Baidu
map

Clin Chem:肾移植患者急性T细胞介导的同种异体排斥反应尿液中的环状RNA

2019-10-23 MedSci MedSci原创

近来,环状RNA (circRNAs)因为其能够调控基因表达成为新的调控因子。在急性肾损伤患者的血液中可以检测到circRNAs。我们测试了尿液中是否存在环状RNA,以及能否作为急性排斥肾移植患者预后的新的预测因子。

近来,环状RNA (circRNAs)因为其能够调控基因表达成为新的调控因子。在急性肾损伤患者的血液中可以检测到circRNAs。我们测试了尿液中是否存在环状RNA,以及能否作为急性排斥肾移植患者预后的新的预测因子。

研究人员使用急性T细胞介导的移植肾排斥反应患者尿液中的RNA进行环状RNA的表达分析,并对移植肾患者进行对照。在一组62例急性排斥反应患者、10例成功抗排斥治疗患者、18例无排斥反应的对照移植患者和13例泌尿系感染的稳定移植患者中,证实了circRNAs的失调。

在急性排斥反应患者的尿液中发现了几个环状RNA的改变。hsa_circ_0001334hsa_circ_0071475两种环状RNA的浓度显著升高。所有患者都证实了这一点。与对照组相比,hsa_circ_0001334在急性排斥反应患者中上调。成功抗排斥治疗后急性排斥反应患者hsa_circ_0001334浓度恢复正常。hsa_circ_0001334与移植后1年肾小球滤过率降低有关。

研究表明,急性排斥反应患者在亚临床时间点上CircRNA浓度明显失调。尿hsa_circ_0001334是一种新的急性肾排斥反应的生物标志物,可以识别急性排斥反应患者,预测肾功能的丧失。

原始出处:

Malte Kölling, George Haddad,Circular RNAs in Urine of Kidney Transplant Patients with Acute T Cell-Mediated Allograft Rejection

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1687988, encodeId=90de168e988eb, content=<a href='/topic/show?id=b3e73898423' target=_blank style='color:#2F92EE;'>#同种异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38984, encryptionId=b3e73898423, topicName=同种异体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23b928427427, createdName=12498768m22(暂无昵称), createdTime=Thu Mar 19 15:34:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262994, encodeId=4ba612629949d, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449378, encodeId=42a914493e8c1, content=<a href='/topic/show?id=b3e24e442bc' target=_blank style='color:#2F92EE;'>#尿液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47442, encryptionId=b3e24e442bc, topicName=尿液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66095470791, createdName=zhaohui6733, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532149, encodeId=1fba15321490f, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1687988, encodeId=90de168e988eb, content=<a href='/topic/show?id=b3e73898423' target=_blank style='color:#2F92EE;'>#同种异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38984, encryptionId=b3e73898423, topicName=同种异体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23b928427427, createdName=12498768m22(暂无昵称), createdTime=Thu Mar 19 15:34:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262994, encodeId=4ba612629949d, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449378, encodeId=42a914493e8c1, content=<a href='/topic/show?id=b3e24e442bc' target=_blank style='color:#2F92EE;'>#尿液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47442, encryptionId=b3e24e442bc, topicName=尿液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66095470791, createdName=zhaohui6733, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532149, encodeId=1fba15321490f, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1687988, encodeId=90de168e988eb, content=<a href='/topic/show?id=b3e73898423' target=_blank style='color:#2F92EE;'>#同种异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38984, encryptionId=b3e73898423, topicName=同种异体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23b928427427, createdName=12498768m22(暂无昵称), createdTime=Thu Mar 19 15:34:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262994, encodeId=4ba612629949d, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449378, encodeId=42a914493e8c1, content=<a href='/topic/show?id=b3e24e442bc' target=_blank style='color:#2F92EE;'>#尿液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47442, encryptionId=b3e24e442bc, topicName=尿液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66095470791, createdName=zhaohui6733, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532149, encodeId=1fba15321490f, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1687988, encodeId=90de168e988eb, content=<a href='/topic/show?id=b3e73898423' target=_blank style='color:#2F92EE;'>#同种异体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38984, encryptionId=b3e73898423, topicName=同种异体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23b928427427, createdName=12498768m22(暂无昵称), createdTime=Thu Mar 19 15:34:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262994, encodeId=4ba612629949d, content=<a href='/topic/show?id=3c0f56643cd' target=_blank style='color:#2F92EE;'>#排斥#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56643, encryptionId=3c0f56643cd, topicName=排斥)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=947269, createdName=lvygwyt2781, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1449378, encodeId=42a914493e8c1, content=<a href='/topic/show?id=b3e24e442bc' target=_blank style='color:#2F92EE;'>#尿液#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47442, encryptionId=b3e24e442bc, topicName=尿液)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=66095470791, createdName=zhaohui6733, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1532149, encodeId=1fba15321490f, content=<a href='/topic/show?id=54bb56644f5' target=_blank style='color:#2F92EE;'>#排斥反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56644, encryptionId=54bb56644f5, topicName=排斥反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=546412326777, createdName=smallant2006, createdTime=Fri Oct 25 13:34:00 CST 2019, time=2019-10-25, status=1, ipAttribution=)]

相关资讯

CLIN CANCER RES:PRMT5环状RNA促进膀胱尿路上皮癌转移

环状RNA(circRNAs)是一类新的非编码RNA,在人类癌症的发病机制中引起了很多关注。然而,circRNA在肿瘤细胞上皮-间质转化(EMT)中的作用仍不清楚。CLIN CANCER RES近期发表了一篇文章,寻找调节膀胱尿路上皮癌(UCB)细胞EMT的新型circRNA,并探讨其在UCB中的调节机制和临床意义。

Oncogene:去势抵抗性前列腺癌中环状RNAs能够增加雄激素受体多样性

环状RNAs(circRNAs)表达的下调与各种人类的疾病相关,包括了许多类型的癌症。尽管环状RNAs与癌症的联系不断的增加,但是circRNAs在去势抵抗性前列腺癌中的特征分析有限,该类型的癌症也是前列腺癌死亡率的主要原因。最近,有研究人员在47个转移去势抵抗性前列腺癌样本中进行了外显子捕获RNA-seq分析,并在人源性异种移植(PDXs)和细胞模型中进行了核糖耗竭和RNase RRNA序列测定

环状RNA的过去,现在与未来

“所有的真理都经历三个阶段。第一,被嘲笑。第二,被激烈反对。第三,被认可且是不言而喻的。”——Arthur Schopenhauer环状RNA是近年来的研究热点。近日,美国Brandeis大学生物系的Sebastian Kadener等人在EMBO上综述了环状RNA的研究进展。BioArt对其进行了编译,以飨读者。

Genome Biology:吉林大学崔久嵬等揭示表观遗传驱动肿瘤转移的新机制

2018年12月11日,吉林大学第一医院干细胞与癌症中心崔久嵬等人在期刊Genome Biology发表题为A novel FLI1 exoniccircular RNA promotes metastasis in breast cancer by coordinately regulatingTET1 and DNMT1的高水平文章。该文章发现:FLI1除了通过经典的癌蛋白途径转移,还通过使用

Blood:环状RNA,circMYBL2,可调节FLT2的表达促进FLT3-ITD AML进展

高达30%的急性髓系白血病(AML)患者发生FMS样酪氨酸激酶-3 (FLT3)内部串联重复(ITD)突变,预后极差。FLT3的致癌型是一个重要的治疗靶点,特异性靶向FLT3激酶的抑制剂可诱导完全缓解;但由于获得性耐药和FLT3的继发性突变,缓解后偶有复发,这突出了靶向FLT3-ITD突变的新策略的必要性。近期研究表明,异常形成的环状RNA(circRNAs)是肿瘤发生的生物学机制,也是潜在的治疗

Nat Neurosci:环状RNA或可成为阿尔兹海默症的临床新指标

阿尔茨海默症(Alzheimer’s disease,AD)是世界卫生组织公认的全球公共卫生重点。AD是一种由多种原因引起的、不可逆转的神经退行性疾病,是痴呆中最常见的一种类型,主要表现为进行性记忆丧失、认知功能障碍、注意力散漫、情感障碍、人格变化等特点,在疾病的最后阶段,患者表现为卧床不起,需要24小时护理,最终致命。研究发现,AD的病理学特征主要为β淀粉样蛋白(beta-amyloid pro

Baidu
map
Baidu
map
Baidu
map